Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 188

1.

Is it possible to predict influenza antigenic variants?

Lina B, Łuksza M.

Virologie (Montrouge). 2017 Feb 1;21(1):5-8. doi: 10.1684/vir.2017.0678. No abstract available.

PMID:
31967567
2.

Influenza increases invasive meningococcal disease risk in temperate countries.

Salomon A, Berry I, Tuite AR, Drews S, Hatchette T, Jamieson F, Johnson C, Kwong J, Lina B, Lojo J, Mosnier A, Ng V, Vanhems P, Fisman DN.

Clin Microbiol Infect. 2020 Jan 11. pii: S1198-743X(20)30026-4. doi: 10.1016/j.cmi.2020.01.004. [Epub ahead of print]

PMID:
31935565
3.

Impact of Pregnancy on Intra-Host Genetic Diversity of Influenza A Viruses in Hospitalised Women: A Retrospective Cohort Study.

Destras G, Pichon M, Simon B, Valette M, Escuret V, Bolze PA, Dubernard G, Gaucherand P, Lina B, Josset L.

J Clin Med. 2019 Dec 25;9(1). pii: E58. doi: 10.3390/jcm9010058.

4.

Novel antiviral compounds and combination therapy for influenza viruses.

Boivin G, Rosa-Calatrava M, Lina B.

Virologie (Montrouge). 2019 Dec 1;23(6):325-328. doi: 10.1684/vir.2019.0802. No abstract available.

PMID:
31859255
5.

Novel antiviral compounds and combination therapy for influenza viruses.

Boivin G, Rosa-Calatrava M, Lina B.

Virologie (Montrouge). 2019 Dec 1;23(6):32-35. doi: 10.1684/vir.2019.0803. No abstract available.

PMID:
31859254
6.

Influenza virus epidemiology: a permanent vaccine challenge.

Boivin G, Lina B.

Virologie (Montrouge). 2019 Oct 1;23(5):271-276. doi: 10.1684/vir.2019.0788. No abstract available.

PMID:
31826848
7.

Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15-64-year-olds in Europe: exploration by birth cohort.

Kissling E, Pozo F, Buda S, Vilcu AM, Gherasim A, Brytting M, Domegan L, Gómez V, Meijer A, Lazar M, Vučina VV, Dürrwald R, van der Werf S, Larrauri A, Enkirch T, O'Donnell J, Guiomar R, Hooiveld M, Petrović G, Stoian E, Penttinen P, Valenciano M; I-Move Primary Care Study Team.

Euro Surveill. 2019 Nov;24(48). doi: 10.2807/1560-7917.ES.2019.24.48.1900604.

8.

Impact of Pregnancy on Intra-Host Genetic Diversity of Influenza A Viruses in Hospitalised Women: A Retrospective Cohort Study.

Destras G, Pichon M, Simon B, Valette M, Escuret V, Bolze PA, Dubernard G, Gaucherand P, Lina B, Josset L.

J Clin Med. 2019 Nov 14;8(11). pii: E1974. doi: 10.3390/jcm8111974. Erratum in: J Clin Med. 2019 Dec 25;9(1):.

9.

Strain-Dependent Impact of G and SH Deletions Provide New Insights for Live-Attenuated HMPV Vaccine Development.

Dubois J, Pizzorno A, Cavanagh MH, Padey B, Nicolas de Lamballerie C, Uyar O, Venable MC, Carbonneau J, Traversier A, Julien T, Lavigne S, Couture C, Lina B, Hamelin MÈ, Terrier O, Rosa-Calatrava M, Boivin G.

Vaccines (Basel). 2019 Oct 30;7(4). pii: E164. doi: 10.3390/vaccines7040164.

10.

Decontamination of Intravaginal Probes Infected by Human Papillomavirus (HPV) Using UV-C Decontamination System.

Pichon M, Lebail-Carval K, Billaud G, Lina B, Gaucherand P, Mekki Y.

J Clin Med. 2019 Oct 24;8(11). pii: E1776. doi: 10.3390/jcm8111776.

11.

Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection.

Mandon ED, Pizzorno A, Traversier A, Champagne A, Hamelin ME, Lina B, Boivin G, Dejean E, Rosa-Calatrava M, Jawhari A.

Vaccine. 2020 Jan 10;38(2):278-287. doi: 10.1016/j.vaccine.2019.10.018. Epub 2019 Oct 18.

PMID:
31630939
12.

Metagenomic Investigation of Torque Teno Mini Virus-SH in Hematological Patients.

Bal A, Oriol G, Josset L, Generenaz L, Sarkozy C, Sesques P, Salles G, Morfin F, Lina B, Becker J, Reynier F, Mallet F, Pachot A, Cheynet V, Brengel-Pesce K, Trouillet-Assant S.

Front Microbiol. 2019 Sep 18;10:1898. doi: 10.3389/fmicb.2019.01898. eCollection 2019.

13.

Optimized nested PCR enhances biological diagnosis and phylogenetic analysis of human parvovirus B19 infections.

Pichon M, Labois C, Tardy-Guidollet V, Mallet D, Casalegno JS, Billaud G, Lina B, Gaucherand P, Mekki Y.

Arch Virol. 2019 Nov;164(11):2775-2781. doi: 10.1007/s00705-019-04368-w. Epub 2019 Aug 10.

PMID:
31401693
14.

Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia.

Nicolas de Lamballerie C, Pizzorno A, Dubois J, Julien T, Padey B, Bouveret M, Traversier A, Legras-Lachuer C, Lina B, Boivin G, Terrier O, Rosa-Calatrava M.

Sci Rep. 2019 Aug 7;9(1):11493. doi: 10.1038/s41598-019-48013-7.

15.

Web-based analysis of adherence to influenza vaccination among French healthcare workers.

Pichon M, Gaymard A, Zamolo H, Bazire C, Valette M, Sarkozy F, Lina B.

J Clin Virol. 2019 Jul;116:29-33. doi: 10.1016/j.jcv.2019.04.008. Epub 2019 Apr 28.

PMID:
31082729
16.

Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019.

Kissling E, Rose A, Emborg HD, Gherasim A, Pebody R, Pozo F, Trebbien R, Mazagatos C, Whitaker H, Valenciano M; European Ive Group.

Euro Surveill. 2019 Feb;24(8). doi: 10.2807/1560-7917.ES.2019.24.1900121.

17.

Residual Activatability of Circulating Tfh17 Predicts Humoral Response to Thymodependent Antigens in Patients on Therapeutic Immunosuppression.

Dahdal S, Saison C, Valette M, Bachy E, Pallet N, Lina B, Koenig A, Monneret G, Defrance T, Morelon E, Thaunat O.

Front Immunol. 2019 Feb 5;9:3178. doi: 10.3389/fimmu.2018.03178. eCollection 2018.

18.

Which sample for the transport of mycoplasma, eSwab® or dry swab?

Pichon M, Gebeile R, Lina B, Jacquet G, Gaymard A.

Ann Biol Clin (Paris). 2019 Feb 1;77(1):95-98. doi: 10.1684/abc.2018.1407.

PMID:
30799304
19.

Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.

Pizzorno A, Terrier O, Nicolas de Lamballerie C, Julien T, Padey B, Traversier A, Roche M, Hamelin ME, Rhéaume C, Croze S, Escuret V, Poissy J, Lina B, Legras-Lachuer C, Textoris J, Boivin G, Rosa-Calatrava M.

Front Immunol. 2019 Jan 29;10:60. doi: 10.3389/fimmu.2019.00060. eCollection 2019.

20.

OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.

Del Campo J, Pizzorno A, Djebali S, Bouley J, Haller M, Pérez-Vargas J, Lina B, Boivin G, Hamelin ME, Nicolas F, Le Vert A, Leverrier Y, Rosa-Calatrava M, Marvel J, Hill F.

NPJ Vaccines. 2019 Jan 23;4:4. doi: 10.1038/s41541-019-0098-4. eCollection 2019.

Supplemental Content

Loading ...
Support Center